Create account

Coverage dated September 22, 2026

Viking's obesity drug data fuels bets it can rival Lilly's Zepbound

Headline from Quartz

Patients who switched from weekly to monthly injections of VK2735 retained most of their weight loss, with side effects similar to placebo

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

  1. Investor's Business Daily

    Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.

  2. Quartz

    Viking's obesity drug data fuels bets it can rival Lilly's Zepbound (opens Quartz)

    Published

    Quartz's feed description

    Patients who switched from weekly to monthly injections of VK2735 retained most of their weight loss, with side effects similar to placebo

Viking's obesity drug data fuels bets it can rival Lilly's Zepbound | Since Then